Cargando…

Intravenous immunoglobulin for the treatment of Alzheimer’s disease: current evidence and considerations

Alzheimer’s disease (AD) is a devastating neurodegenerative form of dementia with increasing incidence rates in most countries. AD is characterized by amyloid plaques and neurofibrillary tangles in the brains of AD individuals accompanied by global neuronal loss. The peptide amyloid-β (Aβ) aggregate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schindowski, Christina, Zimmermann, Jürgen, Schindowski, Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337175/ https://www.ncbi.nlm.nih.gov/pubmed/32669906 http://dx.doi.org/10.2147/DNND.S51786

Ejemplares similares

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
por: Moreth, Jens, et al.
Publicado: (2013)

Neurotrophic factors in Alzheimer’s disease: role of axonal transport
por: Schindowski, K, et al.
Publicado: (2008)

Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa
por: Gänger, Stella, et al.
Publicado: (2018)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Abdeldaim, Dalia T., et al.
Publicado: (2023)

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration
por: Soleimanizadeh, Arghavan, et al.
Publicado: (2021)

Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
por: Kayed, Rakez, et al.
Publicado: (2011)

Intravenous immunoglobulin and Alzheimer’s disease: what now?
por: Loeffler, David A
Publicado: (2013)

Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
por: Moreth, Jens, et al.
Publicado: (2013)

Editorial: Intranasal Drug Delivery: Challenges and Opportunities
por: Fortuna, Ana, et al.
Publicado: (2022)

Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
por: Loeffler, David A
Publicado: (2014)

Optimized fermentation conditions for improved antibody yield in hybridoma cells
por: Stützle, Martina, et al.
Publicado: (2013)

Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries
por: Solemani Zadeh, Arghavan, et al.
Publicado: (2019)

Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence
por: Mahmood, Iftekhar, et al.
Publicado: (2020)

Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
por: Ladel, Simone, et al.
Publicado: (2019)

Data of rational process optimization for the production of a full IgG and its Fab fragment from hybridoma cells
por: Röhm, Martina, et al.
Publicado: (2016)

Establishment of an Olfactory Region-specific Intranasal Delivery Technique in Mice to Target the Central Nervous System
por: Flamm, Johannes, et al.
Publicado: (2022)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Erratum: Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
por: Loeffler, David A
Publicado: (2015)

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau
por: Hong-Qi, Yang, et al.
Publicado: (2012)

Protein aerosol for intranasal nose to brain (N2B) delivery
por: Stützle, Martina, et al.
Publicado: (2015)

Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation
por: Schindowski, K, et al.
Publicado: (2008)

Prioritization of Evidence-Based Indications for Intravenous Immunoglobulin
por: Orange, Jordan S., et al.
Publicado: (2013)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine
por: Velikova, Tsvetelina, et al.
Publicado: (2023)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis
por: Baleva, Marta, et al.
Publicado: (2011)

Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?
por: Ladel, Simone, et al.
Publicado: (2018)

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature
por: Kivity, Shaye, et al.
Publicado: (2009)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies
por: Jacob, Saiju, et al.
Publicado: (2009)

Intravenous Immunoglobulin in the Management of Lupus Nephritis
por: Wenderfer, Scott E., et al.
Publicado: (2012)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

The Production Processes and Biological Effects of Intravenous Immunoglobulin
por: Barahona Afonso, Ana Filipa, et al.
Publicado: (2016)

Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections
por: Perricone, Carlo, et al.
Publicado: (2021)

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease
por: Puli, Lakshman, et al.
Publicado: (2012)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

INTRAVENOUS IMMUNOGLOBULIN IN DERMATOLOGY
por: Dhar, Sandipan
Publicado: (2009)

Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?—Current evidence based on a meta-analysis
por: Zheng, Xiaolan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k6vm3q1787hjis9r9m3j19uub6